1-7 of 7
Jacob R. Haling
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC

Shilpi Khare, Niranjan Sudhakar, Jade Laguer, David M. Briere, Larry Yan, Allan Hebbert, Andrew Calinisan, Lars D. Engstrom, Fadia Qiryaqos, Peter Olson, James G. Christensen, Jacob R. Haling
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3499.
https://doi.org/10.1158/1538-7445.AM2023-3499
Published: 04 April 2023
View article titled, Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC
Journal Articles

Abstract LB193: Chemical genomics identify novel druggable nodes and resistance pathways in the presence of concomitant SOS1 and KRAS inhibition

Shilpi Khare, Niranjan Sudhakar, David M. Briere, Larry Yan, Lars D. Engstrom, Jade Laguer, James Medwid, Laura Vegar, Darin Vanderpool, Matthew A. Marx, John M. Ketcham, James G. Christensen, Peter Olson, Jacob R. Haling
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB193.
https://doi.org/10.1158/1538-7445.AM2022-LB193
Published: 15 June 2022
View article titled, Abstract LB193: Chemical genomics identify novel druggable nodes and resistance pathways in the presence of concomitant SOS1 and KRAS inhibition
Journal Articles

Abstract ND02: MRTX0902: A SOS1 inhibitor for therapeutic intervention of KRAS-driven cancers

John M. Ketcham, Shilpi Khare, Niranjan Sudhakar, David M. Briere, Larry Yan, Jade Laguer, Laura Vegar, Darin Vanderpool, Jill Hallin, Lauren Hargis, Vickie Bowcut, David Lawson, Robin J. Gunn, Anthony Ivetac, Nicole C. Thomas, Barbara Saechao, Natalie Nguyen, Jeffrey Clarine, Lisa Rahbaek, Christopher R. Smith, Aaron C. Burns, Matthew A. Marx, James G. Christensen, Peter Olson, Jacob R. Haling
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): ND02.
https://doi.org/10.1158/1538-7445.AM2022-ND02
Published: 15 June 2022
View article titled, Abstract ND02: MRTX0902: A SOS1 inhibitor for therapeutic intervention of KRAS-driven cancers
Journal Articles

Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor

Darrin D. Stuart, Wenlin Shao, Yuji Mishina, Yun Feng, Giordano Caponigro, Vesselina G. Cooke, Stacey Rivera, Fang Shen, Joshua Korn, Lesley A. Mathews Griner, Giselle Nishiguchi, Benjamin Taft, Lifeng Wan, Sharadha Subramanian, Yan Lou, Lina Setti, Matthew Burger, Victor Tamez, Alice Rico, Robert Aversa, John Tellew, Jacob R. Haling, Valery Polyakov, Amy Lambert, Richard Zang, Ann Van Abbema, Mohamad Hekmat-Nejad, Payman Amiri, Mallika Singh, Nicholas Keen, Michael P. Dillon, Emma Lees, William R. Sellers, Savithri Ramurthy
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): DDT01-04.
https://doi.org/10.1158/1538-7445.AM2018-DDT01-04
Published: 01 July 2018
View article titled, Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor
Journal Articles

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Wenlin Shao, Yuji M. Mishina, Yun Feng, Giordano Caponigro, Vesselina G. Cooke, Stacy Rivera, Yingyun Wang, Fang Shen, Joshua M. Korn, Lesley A. Mathews Griner, Gisele Nishiguchi, Alice Rico, John Tellew, Jacob R. Haling, Robert Aversa, Valery Polyakov, Richard Zang, Mohammad Hekmat-Nejad, Payman Amiri, Mallika Singh, Nicholas Keen, Michael P. Dillon, Emma Lees, Savithri Ramurthy, William R. Sellers, Darrin D. Stuart
Journal: Cancer Research
Cancer Res (2018) 78 (6): 1537–1548.
https://doi.org/10.1158/0008-5472.CAN-17-2033
Published: 14 March 2018
View article titled, Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Open the PDF for Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF in another window
Includes: Supplementary data
Journal Articles

Abstract LB-60: The BRAF:MEK complex reveals new therapeutic strategies for targeting KRASMT tumors.

Jacob R. Haling, Jawahar Sudhamsu, Georgia Hatzivassiliou, Kyung Song, Marcia Belvin, Sarah Hymowitz, Shiva Malek
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-60.
https://doi.org/10.1158/1538-7445.AM2013-LB-60
Published: 15 April 2013
View article titled, Abstract LB-60: The BRAF:MEK complex reveals new therapeutic strategies for targeting KRAS<sup>MT</sup> tumors.
Journal Articles

Abstract 2346: A B-RAF-MEK complex reveals a kinase-independent role for BRAF in MAPK pathway suppression.

Malek Shiva, Jacob R. Haling, Jawahar Sudhamsu, Tony Morales, Ariana Peck, Ivana Yen, Barbara Brandhuber, Sarah Hymowitz
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2346.
https://doi.org/10.1158/1538-7445.AM2013-2346
Published: 15 April 2013
View article titled, Abstract 2346: A B-RAF-MEK complex reveals a kinase-independent role for BRAF in MAPK pathway suppression.